Bartels P H, Bibbo M, Hutchinson M L, Gahm T, Grohs H K, Gwi-Mak E, Kaufman E A, Kaufman R H, Knight B K, Koss L G, Magruder L E, Mango L J, McCallum S M, Melamed M R, Peebles A, Richart R M, Robinowitz M, Rosenthal D L, Sauer T, Schenck U, Tanaka N, Topalidis T, Verhest A P, Wertlake P T, Wilbur D C
Optical Sciences Center, University of Arizona, Tucson 85721, USA.
Acta Cytol. 1998 Jan-Feb;42(1):59-68. doi: 10.1159/000331535.
The extension of automation to the diagnostic assessment of clinical materials raises issues of professional responsibility, on the part of both the medical professional and designer of the device. The International Academy of Cytology (IAC) and other professional cytology societies should develop a policy towards automation in the diagnostic assessment of clinical cytologic materials.
The following summarizes the discussion of the initial position statement at the International Expert Conference on Diagnostic Cytology Towards the 21st Century, Hawaii, June 1997. 1. The professional in charge of a clinical cytopathology laboratory continues to bear the ultimate medical responsibility for diagnostic decisions made at the facility, whether automated devices are involved or not. 2. The introduction of automated procedures into clinical cytology should under no circumstances lead to a lowering of standards of performance. A prime objective of any guidelines should be to ensure that an automated procedure, in principle, does not expose any patient to new risks, nor should it increase already-existing, inherent risks. 3. Automated devices should provide capabilities for the medical professional to conduct periodic tests of the appropriate performance of the device. 4. Supervisory personnel should continue visual quality control screening of a certain percentage of slides dismissed at primary screening as within normal limits (WNL), even when automated procedures are employed in the laboratory. 5. Specifications for the design of primary screening devices for the detection of cervical cancer issued by the IAC in 1984 were reaffirmed. 6. The setting of numeric performance criteria is the proper charge of regulatory agencies, which also have the power of enforcement. 7. Human expert verification of results represents the "gold standard" at this time. Performance characteristics of computerized cytology devices should be determined by adherence to defined and well-considered protocols. Manufacturers should not claim a new standard of care; this is the responsibility of the medical community and professional groups. 8. Cytology professionals should support the development of procedures that bring about an improvement in diagnostic decision making. Advances in technology should be adopted if they can help solve problems in clinical cytology. The introduction of automated procedures into diagnostic decision making should take place strictly under the supervision and with the active participation and critical evaluation by the professional cytology community.
Guidelines should be developed for the communication of technical information about the performance of automated screening devices by the IAC to governmental agencies and national societies. Also, guidelines are necessary for the official communication of IAC concerns to industry, medicolegal entities and the media. Procedures and guidelines for the evaluation of studies pertaining to the performance of automated devices, performance metrics and definitions for evaluation criteria should be established.
将自动化扩展至临床材料的诊断评估引发了医学专业人员和设备设计者双方的职业责任问题。国际细胞学会(IAC)和其他专业细胞学协会应制定关于临床细胞学材料诊断评估自动化的政策。
以下总结了1997年6月在夏威夷举行的“迈向21世纪诊断细胞学国际专家会议”上对初始立场声明的讨论。1. 临床细胞病理学实验室的负责人继续对该机构做出的诊断决策承担最终医疗责任,无论是否涉及自动化设备。2. 在任何情况下,将自动化程序引入临床细胞学都不应导致性能标准降低。任何指南的首要目标都应是确保自动化程序原则上不会使任何患者面临新风险,也不应增加已有的固有风险。3. 自动化设备应具备使医学专业人员能够对设备的适当性能进行定期测试的功能。4. 即使实验室采用了自动化程序,监督人员仍应对在初次筛查时被判定为正常范围(WNL)而被排除的一定比例的玻片进行视觉质量控制筛查。5. 重申了IAC于1984年发布的用于宫颈癌检测的初次筛查设备设计规范。6. 设定数值性能标准是监管机构的适当职责,监管机构也拥有执法权。7. 目前人类专家对结果的验证是“金标准”。计算机化细胞学设备的性能特征应通过遵循明确且经过深思熟虑的方案来确定。制造商不应宣称一种新的医疗标准;这是医学界和专业团体的责任。8. 细胞学专业人员应支持有助于改进诊断决策的程序的开发。如果技术进步有助于解决临床细胞学中的问题,就应采用。将自动化程序引入诊断决策应严格在细胞学专业团体的监督下,并在其积极参与和批判性评估下进行。
IAC应制定指南,以便将有关自动化筛查设备性能的技术信息传达给政府机构和国家协会。此外,还需要指南以便将IAC的关切正式传达给行业、法医学实体和媒体。应建立与自动化设备性能相关研究的评估程序和指南、性能指标以及评估标准的定义。